A drug for treating melanoma is ineffective in colorectal cancers that have the same causative mutation. Studies of how cells adapt to the drug reveal why this is so, and suggest combination therapies that may be more effective. See Letter p.100
References
Chapman, P. B. et al. N. Engl. J. Med. 364, 2507–2516 (2011).
Kopetz, S. et al. J. Clin. Oncol. 28 (ASCO Meet. Abstr. Pt 1), abstr. 3534 (2010).
Prahallad, A. et al. Nature 483, 100–103 (2012).
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. Nature 464, 427–430 (2010).
Nazarian, R. et al. Nature 468, 973–977 (2010).
Poulikakos, P. I. et al. Nature 480, 387–390 (2011).
Corcoran, R. B. et al. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-11-0341 (2012).
Di Nicolantonio, F. et al. J. Clin. Oncol. 26, 5705–5712 (2008).
Joseph, E. W. et al. Proc. Natl Acad. Sci. USA 107, 14903–14908 (2010).
Oberholzer, P. A. et al. J. Clin. Oncol. 30, 316–321 (2012).
Su, F. et al. N. Engl. J. Med. 366, 207–215 (2012).
Infante, J. R. et al. J. Clin. Oncol. 29 (ASCO Meet. Abstr. Pt 1), abstr. CRA8503 (2011).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Solit, D., Jänne, P. Primed for resistance. Nature 483, 44–45 (2012). https://doi.org/10.1038/483044a
Published:
Issue Date:
DOI: https://doi.org/10.1038/483044a
- Springer Nature Limited